In an era where wellness, clarity, and bold authenticity redefine modern living,Arkay Zero Proof Spirits strengthens its legacy as the global pioneer in alcohol-free spirit innovation. With the spotlight on its flagship product – Arkay Alcohol-Free Whisky – the company launches a bold dual message to consumers worldwide: “A Clean Choice. Fearless Living. Clean Sips. […]
(NYSE:FCN), LONDON, July 01, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Joseph Shipley as a Senior Managing Director within the Strategic Communications segment, where he will lead the firm's work with private equity clients and their portfolio companies in London and across the Europe, Middle East and Africa
Sheffield, July 01, 2025 (GLOBE NEWSWIRE) — UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss Rincell-1 addresses a multi $Bn global market opportunity where no disease modifying treatments currently exist Sheffield, UK, July 1 2025 – Rinri Therapeutics, a world leading company focused on transforming
FTI Consulting Appoints Joseph Shipley to Lead Private Equity Offering within the Strategic Communications Segment in London and across EMEA GlobeNewswire July 01, 2025 LONDON, July 01, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Joseph Shipley as a Senior Managing Director within the Strategic Communications segment, where he
At OpenInfra Summit Europe, the community will showcase how OpenStack, Kubernetes, Kata Containers, Ceph, StarlingX, RISC-V and other projects are tackling a $9 trillion demand for open source software Open source infrastructure solutions for digital sovereignty, VMware migration, and AI workloads will be in the spotlight as members of the OpenInfra Foundation and its global
Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for GLIX1 for the treatment of malignant glioma, a category of devastating brain cancers that includes glioblastoma. https://mma.prnewswire.com/media/2721951/Hemispherian_Logo.jpg Significant clinical benefit beyond current therapies. The designation marks
Proven to achieve a breakeven for initial investment in less than six months, ensuring rapid recovery of compliance costs while optimizing efficiency gains Sumsub, a global full-cycle verification platform, today announced the release ofits commissioned Total Economic Impact™ (TEI) study conducted by Forrester Consulting. The study aims to examine the potential return on investment (ROI)
UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss Rincell-1 addresses a multi $Bn global market opportunity where no disease modifying treatments currently exist GlobeNewswire July 01, 2025 Sheffield, July 01, 2025 (GLOBE NEWSWIRE) — UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class
From July 29 to 31, 2025,WEPACK Southeast Asia, organized byRX China,will make its highly anticipated debut at the Jakarta International Expo (JIEXPO), held in parallel with the Paper Chain Expo. This marks the first time these two exhibitions will be co-located, forming a comprehensive platform that links upstream papermaking with downstream packaging applications. The combined
— Report to be released at approximately 7:00 AM CEST on July 15, 2025 — One live video webcast for analysts, investors and journalists at 9:00 AM CEST Ericsson's (NASDAQ: ERIC) financial report for the second quarter 2025 will be published at approximately 7:00 AM CEST on July 15, 2025. The company will issue a